XM tidak memberikan layanan kepada penduduk Amerika Serikat.
A
A

Abbott


Berita

U.S. STOCKS Children's Place, US energy sector, retailers

BUZZ-U.S. STOCKS ON THE MOVE-Children's Place, US energy sector, retailers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes soared on Thursday with the S&P 500 and the Dow hitting intraday record highs after the Federal Reserve kicked off its monetary easing cycle with half-a-percentage point reduction and forecast more interest rate cuts were on the hor
A
A
C
C
I
J
L
M
N
T
A
U
F
R
U
U
S
D

Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr

BRIEF-Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr Sept 19 (Reuters) - Abbott Laboratories ABT.N : ABBOTT - DECLARED A QUARTERLY COMMON DIVIDEND OF 55 CENTS PER SHARE ABBOTT DECLARES 403RD CONSECUTIVE QUARTERLY DIVIDEND Source text for Eikon: ID:nPnbB2dYca Further company coverage: ABT.N
A

Piper Sandler initiates coverage on Abbott with 'overweight' rating

BUZZ-Piper Sandler initiates coverage on Abbott with 'overweight' rating ** Brokerage Piper Sandler initiates coverage on Abbott Laboratories ABT.N with overweight rating and PT of $131 ** Says while execution has been strong, ABT shares have underperformed YTD due to the ongoing litigation related to necrotizing enterocolitis (NEC) in premature babies, which has been an overhang ** Brokerage believes the potential damages related to the lawsuit are already priced in ** Considers ABT to be "one
A

U.S. Athira Pharma, Lowe's Companies, P&G

U.S. RESEARCH ROUNDUP-Athira Pharma, Lowe's Companies, P&G Sept 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Athira Pharma, Lowe's Companies and P&G on Thursday. HIGHLIGHTS * Athira Pharma Inc ATHA.O : Mizuho cuts to neutral from outperform * Five Below Inc FIVE.O : JP Morgan cuts to underweight from neutral * Lowe's Companies Inc LOW.N : TD Cowen raises target price to $265 from $240 * P&G PG.N : JP Morgan rai
A
A
C
D
M
N
T
A
C

India's pharma index climbs after bumper Fed rate cut

BUZZ-India's pharma index climbs after bumper Fed rate cut ** India's Nifty pharma index .NIPHARM climbs 0.5%, snapping three straight sessions of losses ** Rise after the U.S. Federal Reserve started its monetary easing cycle with a large 50-basis-point rate cut MKTS/GLOB ** Indian pharma firms have a sizeable exposure to U.S. markets and earn a significant share of their rev from the geography ** Eighteen of the 21 index constituents are trading in green; top gainers Abbott India ABOT.NS and A
A

Indian shares set to open higher

INDIA STOCKS-Indian shares set to open higher BENGALURU, Sept 10 (Reuters) - Indian shares are set to open higher on Tuesday, tracking a rebound in global stocks ahead of the key U.S. inflation data and the Federal Reserve's interest rate decision. The GIFT Nifty GIFc1 was at 25,035 points, as of 08:06 a.m. IST, indicating the NSE Nifty 50 .NSEI will open above its previous close of 24,936.4. The benchmark Nifty 50 rose for the first time in four sessions on Monday, led by gains in consumer stoc
A
A

FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings

BRIEF-FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings Sept 5 (Reuters) - FDA: FDA: ABBOTT DIABETES CARE INC ISSUES RECALL FOR CERTAIN FREESTYLE LIBRE 3 SENSORS DUE TO RISK FOR INACCURATE HIGH GLUCOSE READINGS Further company coverage: ABT.N
A

Abbott U.S. Availability Of Lingo, Co's First Continuous Glucose Monitoring System Available Without Prescription

BRIEF-Abbott U.S. Availability Of Lingo, Co's First Continuous Glucose Monitoring System Available Without Prescription Abbott Laboratories ABT.N : ABBOTT: U.S. AVAILABILITY OF LINGO, CO'S FIRST CONTINUOUS GLUCOSE MONITORING SYSTEM AVAILABLE WITHOUT PRESCRIPTION ABBOTT: LINGO IS AVAILABLE IN THREE OPTIONS FOR $49, $89, AND $249 Source text for Eiko
A

Abbott follows rival Dexcom with OTC glucose monitor launch in US

UPDATE 3-Abbott follows rival Dexcom with OTC glucose monitor launch in US Adds details on the device in paragraph 3, background in paragraphs 6-7 By Sneha S K Sept 5 (Reuters) - Abbott ABT.N has launched its over-the-counter continuous glucose monitoring system in the U.S., the company said on Thursday, making it the second such device on the market to help people track their blood sugar levels.
A

Abbott launches over-the-counter continuous glucose monitor in the US

Abbott launches over-the-counter continuous glucose monitor in the US Sept 5 (Reuters) - Abbott ABT.N has launched its over-the-counter continuous glucose monitoring system Lingo in the United States, the company said on Thursday. Reporting by Sneha S K; Editing by Janane Venkatraman
A

Abbott Starts Study To Evaluate Use Of Deep Brain Stimulation System To Manage Severe Depression

BRIEF-Abbott Starts Study To Evaluate Use Of Deep Brain Stimulation System To Manage Severe Depression Sept 4 (Reuters) - Abbott Laboratories ABT.N : ABBOTT INITIATES CLINICAL STUDY TO EVALUATE THE USE OF ITS DEEP BRAIN STIMULATION SYSTEM TO MANAGE SEVERE DEPRESSION Source text for Eikon: ID:nPnbMNcLha Further company coverage: ABT.N
A

Diagnostics firm Labcorp weighs ramping up mpox testing capacity

UPDATE 2-Diagnostics firm Labcorp weighs ramping up mpox testing capacity Adds details on other tests from paragraph 6 By Sneha S K Aug 26 (Reuters) - Diagnostics firm Labcorp LH.N said it is working with U.S. health regulators to determine if it needed to ramp up its mpox testing capacity, as countries outside Africa detect a new type of the virus for the first time.
A
L

Dexcom launches over-the-counter continuous glucose sensors in the US

UPDATE 2-Dexcom launches over-the-counter continuous glucose sensors in the US Adds pricing details in paragraphs 3, background throughout Aug 26 (Reuters) - Dexcom DXCM.O said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99. S telo was cleared by the U.S. health regulator in March for use by adults aged 18 and older who do not use insulin, making it the the first continuous glucose monitor available for over
A

Stifel raises PT on Dexcom on positive physician sentiment for its devices

BUZZ-Stifel raises PT on Dexcom on positive physician sentiment for its devices ** Brokerage Stifel raises PT on glucose monitor maker Dexcom DXCM.O to $100 from $90 ** Shares of Dexcom were up 1.2% at $73.16 ** Says while work is needed to optimize the sales force/repair distributor relationships, physician sentiment on DXCM remains positive ** Co
A
S

U.S. Aadi Bioscience, Target, Visteon

U.S. RESEARCH ROUNDUP-Aadi Bioscience, Target, Visteon Aug 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aadi Bioscience, Target and Visteon, on Thursday. HIGHLIGHTS * Aadi Bioscience Inc AADI.O : Jefferies cuts to hold from buy * Assurant Inc AIZ.N : Piper Sandler cuts to neutral from overweight * Estée Lauder EL.N : Piper Sandler raises to overweight from neutral * Target Corp TGT.N : Jefferies raises target
A
A
H
S
T
T
U
A
P
U
D
E
A

Abbott Says FDA Approved Change To Label For Heartmate 3 Heart Pump

BRIEF-Abbott Says FDA Approved Change To Label For Heartmate 3 Heart Pump Aug 21 (Reuters) - Abbott Laboratories ABT.N : ABBOTT: FDA APPROVED CHANGE TO LABEL FOR HEARTMATE 3 HEART PUMP ABBOTT: ADVANCES HEART FAILURE MANAGEMENT WITH ASPIRIN FREE REGIMEN FOR PATIENTS RECEIVING THE HEARTMATE 3 HEART PUMP Source text for Eikon: [ID:] Further company co
A

Medtronic nudges profit forecast on medical devices demand, new launches

UPDATE 3-Medtronic nudges profit forecast on medical devices demand, new launches Adds shares in paragraph 1, company comments from conference call in paragraphs 7,8, 10 and 13, analyst comment in paragraph 11, graphic By Sriparna Roy and Puyaan Singh Aug 20 (Reuters) - Medtronic MDT.N slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its new launches, sending its shares up 1.6% .
A

Harris' anti-price gouging plan could build on US state law

EXPLAINER-Harris' anti-price gouging plan could build on US state law By Jody Godoy Aug 16 (Reuters) - As Vice President Kamala Harris focuses on price gouging in her presidential campaign, state laws and laws proposed by her colleagues in the Senate show potential paths for a crackdown on high prices. The Democratic candidate planned to lay out her anti-price gouging and other economic proposals in a speech in Raleigh, North Carolina, on Friday.
A
K
W

Abbott India gains on upbeat Q1 results

BUZZ-Abbott India gains on upbeat Q1 results ** Shares of Abbott India ABOT.NS climb ~4% to 29,139.30 rupees, their highest since February ** Drugmaker reports 13% Y/Y rise in Q1 consol net profit ; 5.3% Y/Y rev growth ** Stock top pct gainer in pharma index .NIPHARM , which is up ~1% ** Trading volume 2.4x the 30-day moving average ** ABOT among 1
A

India economic, corporate events on August 8

DIARY- India economic, corporate events on August 8 BENGALURU, Aug 8 (Reuters) - Diary of India economic, corporate events on August 8. ECONOMIC, CORPORATE .BSE500 EVENTS: RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INREPO=ECI 8 Aug 2024 10:00 Repo Rate 8 Aug 6.50% 6.50% INRREP=ECI 8 Aug 2024 10:00 Reverse Repo Rate 8 A
A
A
A
B
B



Kondisi

Aset Populer

Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.

Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.

Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.

Peringatan Resiko: Modal Anda beresiko. Produk dengan leverage mungkin tidak cocok bagi semua orang. Silahkan pertimbangkan Pengungkapan Resiko kami.